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Although substantial advances have been made in behavioral and pharmacological treatments for addic-
tions, moving treatment development to the next stage may require novel ways of approaching addictions,
particularly ways based on new findings regarding the neurobiological underpinnings of addictions that also
assimilate and incorporate relevant information from earlier approaches. In this review, we first briefly review
theoretical and biological models of addiction and then describe existing behavioral and pharmacologic ther-
apies for the addictions within this framework. We then propose new directions for treatment development
and targets that are informed by recent evidence regarding the heterogeneity of addictions and the neurobi-
ological contributions to these disorders.Overview
Despite intensive research and significant advances, drug addic-
tions remain a substantial public health problem. Drug addictions
cost U.S. society hundreds of billions of dollars annually and
impact not only the addicted individuals, but also their spouses,
children, employers, and others (Uhl and Grow, 2004; Volkow
et al., 2011). Furthermore, costs may be even higher as nondrug
disorders (e.g., related to food and gambling) have recently been
conceptualizedwithin an addiction framework, with neurobiolog-
ical data supporting similarities across substance dependences,
obesity, and pathological gambling (Frascella et al., 2010; Grant
et al., 2010b; Kenny, 2011; Potenza, 2008). Given the additional
health burdens of these conditions (e.g., obesity and tobacco
consumption represent two top causes of preventable death
[Danaei et al., 2009; Kenny, 2011]), addictions arguably represent
our nation’s (and the world’s) main health problem. Thus, the
development of improved prevention and treatment strategies
is of paramount importance.
In order to best prevent and treat addictions, it is important to
have a clear understanding of which disorders constitute addic-
tions, and this point has been debated considerably over time.
The term addiction, derived from a Latin word meaning ‘‘bound
to’’ or ‘‘enslaved by,’’ was initially not linked to substance use
(Maddux and Desmond, 2000). However, over the past several
hundred years, addiction became associated with excessive
alcohol and then drug use such by the 1980s it was largely
synonymous with compulsive drug use (O’Brien et al., 2006).
However, observations that individuals with gambling problems
share clinical, phenomenological, genetic, and other biological
similarities with people with drug dependences has prompted
reconsideration of the core features of addiction, with continued
performance of the behavior despite adverse consequences,
compulsive engagement, or diminished control over the
behavior, and an appetitive urge or craving state prior to behav-ioral engagement representing core elements (Holden, 2001;
Potenza, 2006; Shaffer, 1999). If these are considered the central
elements of addictions, then behaviors like gambling may be
considered from an addictions perspective. Consistent with
this notion and existing clinical, preclinical, and neurobiological
data, pathological gambling is being considered for reclassifica-
tion with substance use disorders into an addictions category in
DSM-V (Holden, 2010).
In addition to similarities across addictive disorders, there are
also differences relevant to individual addictions that are related
to features like the sites of action of the drugs being abused and
the social acceptability and availability of the behavior or
substance, and these represent important considerations with
respect to the neurobiologies and treatments of addictions. For
example, while compulsivity may cut across addictions, aspects
of tolerance andwithdrawal may differ and reflect specific neuro-
adaptations related to individual substances or behaviors (Dalley
et al., 2011; Kenny, 2011; Sulzer, 2011). Thus, considering
the mechanisms underlying addictions in general as well as
features unique to individual disorders is important in treatment
development.
Multiple, non-mutually exclusive models (e.g., incentive
salience [Robinson and Berridge, 2001], allostasis [Edwards
and Koob, 2010; Koob and Le Moal, 2001], reward deficiency
[Blum et al., 1996]) have been proposed for addictions. While
they each have unique features, they also include common
features related to the proposed core elements of addiction
described above. Across thesemodels,motivational neurocircui-
try functions to favor drug use (or behavioral engagement) over
other aspects of life (e.g., studying for tests, going to work, or
caring for one’s family). Consistently, addiction has been termed
a condition of motivated behavior going awry (Volkow and Li,
2004) and neurobiological models of motivational circuitry have
been proposed for addictions and addiction vulnerabilityNeuron 69, February 24, 2011 ª2011 Elsevier Inc. 695
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Koob, 2010). In these models, cortico-striato-pallido-thalamo-
cortical loops form a central feature underlying motivated behav-
iors (Alexander et al., 1990; Alexander et al., 1986). Other brain
regions and circuits contribute importantly to motivated behav-
iors, with regions like the amygdala providing important affective
information, the hippocampus important contextual memory
information, the hypothalamus and septum important homeo-
static information, and the insula important information related
to interoceptive processing (Chambers et al., 2003; Everitt and
Robbins, 2005; George and Koob, 2010; Naqvi and Bechara,
2009).Additionally, cingulatecorticesprovide importantcontribu-
tions, with the anterior and posterior components contributing to
emotional regulation, cognitive control, and stress responsive-
ness (Botvinick et al., 2001; Bush et al., 2000; Sinha, 2008). While
often relatively simplistic, suchmodels, particularly when consid-
ered fromasystemsperspective (i.e., thesebrain regions function
in circuits rather than in isolation), provide a neurobiological basis
for developing new treatments for addictions and investigating
themechanismsbywhich effective therapies for addictionswork.
Aspects of the development of addictions can be understood
on the basis of both positive and negative reinforcements linked
todruguse.Drugexperimentation typically beginsduring adoles-
cence, initially resulting in hedonic experiences that generate
relatively immediate positive reinforcement for use with little or
no negative consequences (Rutherford et al., 2010; Wagner
and Anthony, 2002). Yet as drug use continues, neuroadapta-
tions occur relating to the development of drug tolerance, result-
ing in a reduction in the pleasurable sensations achieved from
a similar initial level of drug use. Although the precise adaptations
remain a topic of current investigation, motivational
neurocircuitry and multiple neurotransmitter systems, particu-
larly dopamine, are implicated (Rutherford et al., 2010; Sulzer,
2011). As this cycle continues, subjects increase the frequency
and amount of drug use to gain the same rewarding experience.
For many drugs, increased use also leads to withdrawal symp-
toms when drug use is curtailed or cut down. As withdrawal
symptoms can at least be temporarily relieved by continued,
and escalating, drug use, a vicious cycle is established. Over
time, hedonicmotivations for substance usediminishwhile nega-
tive reinforcement motivations increase, with drug-taking behav-
iors becoming less rewarding and more compulsive or habitual
over time. This shift has been proposed to involve a progression
of involvement of ventral to dorsal cortico-striato-pallido-tha-
lamo-cortical circuitry (Brewer and Potenza, 2008; Everitt and
Robbins, 2005; Fineberg et al., 2010; Haber and Knutson,
2010). From a molecular level, dopamine function, particularly
striatal D2/D3 receptor function, appears relevant to this process
and has been implicated across addictive disorders (Kenny,
2011; Steeves et al., 2009; Wang et al., 2009). However, multiple
other neurotransmitter systems contribute and may represent
better treatment targets, particularly as D2/D3 receptor antago-
nists have not demonstrated clinical efficacy for addictions.
From a cognitive perspective, attempts to control or eliminate
addictive behaviors are usually motivated by the delayed nega-
tive consequences of use. The individual’s cognitive recognition
of these negative consequencesmay lead to attempts to develop
changed attitudes and drug-using behaviors. This process696 Neuron 69, February 24, 2011 ª2011 Elsevier Inc.necessitates executive control, which may be mediated via
top-down control of the prefrontal cortex over subcortical
processes promoting motivations to engage in the addictive
behavior (Chambers et al., 2003; Everitt and Robbins, 2005).
Both positive reinforcement processes (e.g., seeking a drug
high) and negative reinforcement processes (e.g., seeking
relief from stressful or negative mood states) may be linked to
environmental or internal cues in fashions that are behaviorally
engrained, resistant to change, and linked to powerful motiva-
tional craving states (Chambers et al., 2007). Thus, therapies
may be needed to target strong learned associations between
drug use and immediate positive or negative reinforcements.
Phases of Treatment
The treatment for addictions can be divided into three phases:
detoxification, initial recovery, and relapse prevention. The first
phase, detoxification, has the goal of achieving abstinence that
is sufficiently sustained to yield a safe reduction in immediate
withdrawal symptoms. The second phase, initial recovery, has
goals of developing sustained motivation to avoid relapse,
learning strategies for tolerating craving induced by external or
internal cues, and developing new patterns of behavior that
entail replacement of drug-induced reinforcement with alterna-
tive rewards. The third phase, relapse prevention, takes place
after a period of sustained abstinence and requires subjects to
develop long-term strategies that will allow them to replace
past drug behaviors with new, healthy behaviors.
As discussed above, the drug addiction cycle is maintained
through repeated use and alterations to motivational neurocircui-
try, includingdopaminergicsystems.Given theneed todisengage
from sustained patterns of use and related neuroadaptations,
detoxification frequently requires pharmacological intervention.
These initial drug treatmentsmay involve choosing a replacement
substance that hasa similarmodeof actionon theneurobiological
substrate, while having a slower and more sustained effect.
Behaviorally speaking, this results in withdrawal symptoms that
are made less acute but more prolonged and gradual. For
example, drugs with longer half-lives than herion (e.g., metha-
done) can be used in addicted individuals during detoxification.
Successful resolution of detoxification requires sustained
motivation to tolerate withdrawal symptoms. The second phase,
initial recovery, is often aided by external, structural controls
(e.g., hospitalization) that limit access to drugs once withdrawal
symptoms have been alleviated. Yet, ultimately, the initial
recovery phase must teach the addicted individual ways to
sustain motivations to avoid relapse, learn strategies for toler-
ating and resisting drug cravings induced by external or internal
cues, and develop new patterns of behavior that entail replace-
ment of drug-induced reinforcement with alternative rewards.
Learning these new behavioral strategies can also be aided by
the longer-term administration of medications such as those
used in the detoxification process (e.g., drugs that block or
reduce drug rewards, reduce craving by substituting for drug
effects) or by the additional augmentation with drugs that help
to reduce mental and physical symptoms not necessarily related
to drug use (e.g., independent depression or anxiety disorders).
The third phase, relapse prevention, is perhaps the most
difficult to achieve given the long-term brain adaptations
Figure 1. The Brain Regions Proposed
to Mediate the Behavioral and
Pharmacological Treatments of Addictions
For simplicity, only a few key brain regions are
included in the figure. See text for details. Abbrevi-
ations: AD, adrenergic receptors; CBT, cognitive
behavioral therapy; CM, contingency manage-
ment; DA, dopamine; DAT, dopamine transporter;
GABA, gamma-aminobutyric acid; Glu, glutamate;
l.cer, locus ceruleus; MI, motivational interviewing;
Nac, nucleusaccumbens; nAChR, nicotinic cholin-
ergic receptor; NE, norepinephrine; NET, norepi-
nephrine transporter; VTA, ventral tegmental area.
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occur and many relapse prevention programs involve
a continued support system (e.g., Alcoholics Anonymous) to
aid in maintaining new behaviors developed during initial
recovery. Threats to recovery involve both external and internal
cues that lead to waning motivation, attenuation of external or
internal controls, and revival of associative learning cues linking
drug use to hedonic experiences and can be triggered by both
external cues and internal cues. External cues include exposure
to drugs or to people, places, or things associated with drug use.
Internal cues include hedonic experiences that may be
enhanced by resumed drug use or dysphoric experiences that
may be mediated by such factors as stress, interpersonal
conflict, or symptoms of comorbid mental disorders such as
depression.
At all three phases, social processes can improve executive
functioning through a variety of mechanisms, including
enhancing motivation, reducing friction and stress, providing
alternative rewards associated with avoiding drug use, and
providing external constraints. These factors can be conceived
of as enhancing cortically mediated executive control over
addictive behaviors (Volkow et al., 2011).
In the next sections, we will briefly review the major behavioral
and pharmacological treatments for addictions and describe the
targets of these treatments. In a simplified description, the neural
processes targeted by treating addictions can be characterized
as ‘‘top-down’’ or ‘‘bottom-up.’’ Top-down interventions attempt
to change cognitions and behaviors mediated by enhanced
prefrontal cortical function and altered executive control.
Bottom-up interventions target the subcortical processes,
including the striatal reward pathways, that mediate dysphoric
symptoms and learned association pathways that do not require
or necessarily involve cortical activity. As a broad generalization,
current behavioral treatments appear strongest at changing
top-down activity while pharmacological treatments tend to
target bottom-up processes (Figure 1).Neuron 69,Behavioral Therapies Strategies
and Targets
Compulsive drug use despite negative
consequences and despite the desire to
quit can be understood as entailing two
processes that are targets for behavioral
therapies: (1) the excessive desire to
use or craving for substances; and (2)
insufficient impulse control associatedwith neurocognitive impairment. In the sections below we briefly
review three broad categories of behavioral interventions that
have achieved consistent empirical support for substance use
problems through randomized controlled trials. These are (1)
brief and motivational models, (2) contingency management
models, and (3) cognitive behavioral models.
Brief Motivational Models
A surprising revelation of the past 20 years of treatment research
in the addictions has been the efficacy and durability of brief
behavioral therapies for many individuals with substance use
problems (Burke et al., 2003; Miller and Rollnick, 2002). Rela-
tively brief, focused interventions consisting of as little of a single
session have not only been demonstrated to be effective, but in
several studies have also been shown to be as effective as
lengthier, more intensive approaches. The efficacy of brief
motivational approaches appears to extend to addictions that
do not involve ingested substances (Burke et al., 2003), including
pathological gambling and eating disorders (Brewer et al.,
2008b; Frascella et al., 2010), suggesting that similar neural
mechanismsmay underlie therapeutic effects across addictions.
Although the precise neural mechanismsmediating the effects of
brief motivational interventions are not known, processes
involving the receipt of health-related information and recom-
mendations from a professional may prompt individuals to alter
their decision-making processes to focus on more future-
oriented goals. Thus, brain motivational circuitry in general and
specific regions implicated in risk-reward decision making
(e.g., ventromedial prefrontal cortex), cognitive control (e.g.,
anterior cingulate cortex), and planning and executive func-
tioning (e.g., dorsolateral prefrontal cortex) in particular may
represent important brain regions for consideration (Bechara,
2003; Bush et al., 2002; Dalley et al., 2011).
Contingency Management Models
Another major development in the treatment of substance
use problems has involved findings regarding the efficacy of
contingency management interventions (Dutra et al., 2008;February 24, 2011 ª2011 Elsevier Inc. 697
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cology and operant conditioning, contingency management
approaches recognize that abused substances are powerful
reinforcers and are implemented with the idea that immediate
reinforcement of abstinence (or other behaviors incompatible
with substance use) can reliably, and comparatively easily,
interrupt substance use for a large number of individuals. In the
case of substance dependence, individuals are provided
concrete rewards, often cash, that generally escalate in value
and are contingent on submitting drug-free urine specimens
(Higgins et al., 1991). Beyond producing some of the largest
and most consistent effect sizes in substance abuse treatment
(Dutra et al., 2008), these approaches have broad utility
and can be targeted to improve treatment adherence, including
medication compliance that often undercuts the efficacy of
available pharmacotherapies (Carroll et al., 2004).
Contingency management for addictions can be conceptual-
ized within a behavioral neuroeconomic framework (Glimcher
and Rustichini, 2004). Individuals with addictions as compared
to those without typically place comparably greater values on
immediate rewards, and future rewards are more rapidly deval-
ued, a process termed delay or temporal discounting. This rapid
discounting has been observed across groups of individuals with
different addictions, both substance and nonsubstance, in
active and remitted addictions, and with respect to both drugs
and money (Johnson et al., 2007; Johnson et al., 2010; Petry,
2001a, 2001b; Ross et al., 2009). From a neurobiological
perspective, the selection of small immediate rewards typically
activates ‘‘reward’’ regions like the ventral striatum and ventro-
medial prefrontal cortex whereas the selection of larger, delayed
rewards activates more dorsal cortical regions (Kable and
Glimcher, 2007; McClure et al., 2004). Steep temporal discount-
ing has been associated with poor treatment outcome for
addictions (Krishnan-Sarin et al., 2007), may be amenable to
treatment (Bickel et al., 2011), and may involve cortical and
subcortical systems involved in decision making (Bickel and Yi,
2008) (see also Balleine et al. (2007) and related articles in the
volume).
Cognitive Behavioral Models
Another set of approaches that has emerged with strong support
from randomized trials includes cognitive behavioral therapies
(CBTs), which seek to help the individual recognize behavioral
patterns and cognitions that maintain substance use and to
learn and then implement skills and strategies to change
those patterns and interrupt substance use (Dutra et al., 2008;
Irvin et al., 1999; Magill and Ray, 2009; Tolin, 2010). These
approaches are based on principles of operant as well as clas-
sical conditioning, for example, seeking to heighten the individ-
uals’ awareness of cues previously paired with substance use,
reduction of exposure to such cues, and implementation of skills
to be aware of and tolerate cue-induced craving. CBT
approaches emphasize the development of cognitive strategies
to countervail the strong drives for drugs associated with condi-
tioned cravings, as well as to fortify behavioral controls through
learning to employ alternative copingmechanisms or to seek and
value alternative, socially sanctioned rewards that are incompat-
ible with drug abuse. CBT approaches appear to have particu-
larly durable effects in that substance use often continues to698 Neuron 69, February 24, 2011 ª2011 Elsevier Inc.decrease even after CBT treatment concludes, so-called
‘‘sleeper effects’’ (Carroll et al., 1994).
As with other behavioral therapies, the neural mechanisms
underlying CBT remain poorly understood and, in comparison
to brief motivational interventions and contingency manage-
ment, may be particularly complex given the multifaceted nature
of CBT. For example, CBT typically consists of multiple sessions
or modules, with each having a specific focus (Carroll et al.,
1998; Petry, 2005). Accordingly, different modules may prefer-
entially induce changes in specific neural circuits. For example,
modules that teach coping strategies for managing cravings
may specifically influence or involve brain regions implicated in
cue-induced drug craving (e.g., medial prefrontal and anterior
cingulate cortices in cocaine dependence [Childress et al.,
1999; Wexler et al., 2001]) and/or work through altering func-
tional connectivity within brain circuits related to craving.
Consistent with this notion, an fMRI study investigating cue-
induced craving and using instructions based on CBT cognitive
strategies to focus on long-term consequences of tobacco use
rather than short-term pleasurable tobacco associations found
that dorsolateral prefrontal cortical regions exerted control
over ventral striatal activation in the regulation of craving (Kober
et al., 2010). These findings are reminiscent of a study of
tobacco smokers who were exposed to tobacco cues in an
emotional Stroop task and received a combination of behavioral
therapy and nicotine replacement (Janes et al., 2010). Individ-
uals who showed greater functional connectivity between
prefrontal cortical regions and brain areas involved in craving
and interoceptive processing (anterior cingulate cortex and
insula) demonstrated greater success in treatment (Janes
et al., 2010).
Other aspects of CBT may involve the recruitment and
strengthening of other circuits. For example, consider the
learning of alternate coping strategies. Training on a visual
perception learning task led to strengthened connectivity of
circuitry involved in spatial attention, and these changes were
observed in brain activity during rest (Lewis et al., 2009). Restful
waking brain activity has been termed the default mode network,
and although changes in default mode processing have been
proposed to underlie both effective behavioral and pharmaco-
logical treatment of nicotine dependence (Costello et al.,
2010), the relationship between default mode processing and
learning changes in CBT has not been examined.
Other CBT modules (for example, those relating to financial
management in pathological gambling) maymore closely involve
neurocircuitry implicated in the processing of monetary rewards
or financial decision making (Kable and Glimcher, 2007; Knutson
and Greer, 2008). As individuals with addictions typically differ
from control subjects in the function of such circuitry (Tanabe
et al., 2007; Wrase et al., 2007), it is tempting to speculate that
effective CBT might ‘‘normalize’’ these circuits and that such
normalization would be related to completion of the correspond-
ing CBTmodule. CBT-related changes over a longer time period,
including ‘‘sleeper effects,’’ may involve circuitry underlying
cognitive function and affective control, as has been observed
with CBT in other disorders like depression and obsessive-
compulsive disorder (Goldapple et al., 2004; Ritchey et al.,
2010; Saxena et al., 2009; Siegle et al., 2006).
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Several novel approaches to achieving recovery from addictions
are receiving empirical support, and in some cases these may
complement existing strategies through more efficient targeting
of cognitive, emotional, and behavioral domains or deficits, as
well as their neural correlates. Novel cognitive remediation strat-
egies, aimed at strengthening brain function, may have potential
in addiction treatment. Cognitive remediation strategies involve
repeated intensive exposure to computerized exercises in-
tended to strengthen memory, attention, planning, and other
aspects of executive functioning. Given its novelty, this
approach has promise and is consistent with adult neuroplastic-
ity (Ersche and Sahakian, 2007) and findings in nonaddicted
populations. For example, cognitive remediation strategies
improve not only neurocognitive functioning in individuals with
schizophrenia, but also their general social and occupational
functioning (Bell et al., 2001). Specifically, measures of neuro-
cognition (assessing attention, memory, and problem solving)
andmeasures of social cognition and adjustment were improved
over a two-year period (Hogarty et al., 2004). There is preliminary
evidence that computerized cognitive remediation improves
cognitive functioning in substance users with neuropsycho-
logical deficits and also improves treatment engagement
and outcome (Bickel et al., 2011; Grohman et al., 2006; Wexler,
2011). For example, working memory training was found to
reduce impulsive choice measures of temporal discounting
in substance abusers (Bickel et al., 2011). The extent to
which such changes reflect increased top-down control
through enhanced prefrontal cortical function requires direct
investigation.
Other approaches receiving empirical support in addictions
treatment are mindfulness-based therapies. Based in part on
Buddhist tenets and practices, mindfulness-based therapies
have been developed to target stress and negative mood states
in depression and examined in preliminary studies of addictions
(Brewer et al., 2010). In a pilot study, mindfulness training,
compared with CBT, demonstrated comparable efficacy on
measures of retention and abstinence and was more effective
in diminishing subjective and biological stress responsiveness
(self-reported anxiety following personalized stress exposure
and sympathetic/vagal ratios, respectively) (Brewer et al.,
2009). These findings suggest that mindfulness-based therapies
may be particularly helpful in targeting negative reinforcement
processes, like stress-induced cravings, in addictions, and this
may be of particular relevance to relapse prevention as stress-
induced cravings measures predict relapse (Sinha et al., 2006).
Given the neurobiology of stress responsiveness and increased
cortico-striato-limbic activations to stress in addicted individuals
(Koob and Zorrilla, 2010; Sinha, 2008), it is tempting to speculate
that mindfulness-based therapies may normalize stress-related
responses in addicted individuals. Mindfulness-based therapies
may be particularly applicable to women, as cocaine-dependent
women as compared to cocaine dependent men demonstrate
relatively increased cortico-striato-limbic activations to stress
cues (Potenza et al., 2007). Changes related to mindfulness-
based therapies may involve white matter changes in brain
regions implicated in emotional regulation and cognitive control
as meditation, a component of mindfulness-based therapies,has been reported to induce white matter integrity changes in
the corona radiata, a tract connecting the anterior cingulate
cortex to other brain structures (Tang et al., 2010).
Additional behavioral therapeutic advances might be gleaned
from considering approaches to nonsubstance addictions. For
example, imaginal desensitization has shown some efficacy in
the treatment of pathological gambling (Brewer et al., 2008b;
Grant et al., 2009), and this approach of controlled exposure to
gambling-related cues may help uncouple cues from engage-
ment in addictive behaviors and thus might be anticipated to
influence prefrontal control over motivation (George and Koob,
2010). Participation in 12-step programs (e.g., Alcoholics
Anonymous) may also induce specific neuroadaptations. Like
CBT, 12-step programs havemultiple components (steps) (Alco-
holics Anonymous, 1986), and these may be differentially linked
to specific brain circuits. For example, step eight involves
a willingness to make amends to those harmed, and performing
such behaviors may involve changes neurocircuitry implicated in
social reciprocity and moral decision making (Moll et al., 2005;
Potenza, 2009a). Although a 12-step program is not a behavioral
therapy per se, many individuals receiving formal treatment for
addictions also attend 12-step programs. Thus, considering
the contributions of 12-step participation to treatment outcome
and corresponding changes in neurocircuitry is important.
Pharmacological Treatments and Targets
Multiple pharmacological targets have been identified for the
treatment of addictive disorders. ‘‘Classic’’ approaches tend to
target the drug ‘‘reward’’ system, such as normalization of func-
tion through agonist approaches and negative reinforcement
strategies. These approaches are informed by study of neuro-
transmitters affected by substances of abuse (Koob and Volkow,
2010; Reissner and Kalivas, 2010; Sulzer, 2011), with recent
approaches emphasizing the targeting of individual vulnerabil-
ities and cognitive function (George and Koob, 2010).
Medications Targeting Positive Reinforcement
or Drug Reward
Positive reinforcement is defined as any stimulus that increases
the probability of the preceding behavior and typically involves
a hedonic reward. Self-administration is the primary measure
for drug reinforcement, and almost all reinforcing drugs induce
subjective drug reward or ‘‘liking’’ in humans. The exact function
of dopamine in addictive behavior continues to be debated
(Dalley and Everitt, 2009; Kenny, 2011; Lajtha and Sershen,
2010; Schultz, 2010, 2011). According toRobinson andBerridge,
dopaminemainlymediates incentive-salience or ‘‘wanting’’ while
drug pleasure or ‘‘liking’’ is mediated by other neurotransmitters
including endogenous opioids, gamma-aminobutyric acid
(GABA), and endocannabinoids (Berridge et al., 2009; Horder
et al., 2010;RobinsonandBerridge, 1993). Thehypothesis is sup-
ported by a humanPET imaging study inwhich dopamine release
by amphetaminewas correlatedwith drug ‘‘wanting’’ but notwith
mood elevation (Leyton et al., 2002). In addition, acute phenylal-
anine-tyrosine depletion, which reduces the precursor levels for
dopamine, resulted in attenuated cue and cocaine-induced
drug craving but not euphoria or self-administration of cocaine
(Leyton et al., 2005). Further, dopamine receptor antagonists
do not consistently block cocaine-induced ‘‘high’’ in humansNeuron 69, February 24, 2011 ª2011 Elsevier Inc. 699
Table 1. Pharmacotherapies Used for the Treatment of Addictive Disorders
Medication Delivery System Mechanism of action Type of Addiction Efficacy
Methadone Oral solution or tablet m opioid agonist Opioid Effective in retaining patients
in treatment and reducing
heroin use (Mattick et al.,
2003)
Buprenorphine Sublingual tablet alone or
with naltrexone
Partial m opioid agonist and k
opioid antagonist
Opioid Effective in retaining patients
and reducing heroin use




Opioid antagonist Opioid Better opioid use outcomes
in high retention groups
(Johansson et al., 2006)
Alcohol Significantly reduces
relapses but not to drinking
(Srisurapanont and
Jarusuraisin, 2005)
Disulfiram Oral tablet Increases acetaldehyde by
inhibition of aldehyde
dehydrogenase




Acamprosate Oral tablet NMDA receptor modulator Alcohol Two-fold increase in
abstinence rates at 1 year




lozenge, nasal spray, and
oral inhaler
nAChR agonist Nicotine Two-fold increase in the
odds of quitting smoking
(Fiore et al., 2008)
Bupropion Oral tablet DA and NE reuptake blocker,
and nAChR antagonist
Nicotine Two-fold increase in the
odds of quitting smoking
(Eisenberg et al., 2008)
Varenicline Oral tablet Partial agonist for the a4b2
and full agonist for the a7
nAChR
Nicotine 2- to 3-fold increase in the
odds of quitting smoking at
6 months (Cahill et al., 2010)
Abbreviations: DA, dopamine; nAChR, nicotinic cholinergic receptor; NE, norepinephrine; NMDA, n-methyl-d-aspartate.
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also comes from the food literature where differences in dopa-
mine-related neural responses to highly versus less palatable
foods are observed (Kenny, 2011). These clinical as well as other
preclinical findings (Berridge et al., 2009) provide indirect
evidence for a limited role of dopamine for drug ‘‘liking.’’ Identi-
fying the neurotransmitter mechanisms that mediate drug
‘‘wanting’’ and ‘‘liking’’ responses may facilitate development of
new pharmacotherapy targets for addictive disorders.
1. Agonist approaches. Agonist medications have their main
impact on the same types of neurotransmitter receptors as those
stimulated by abused substances. The general strategy of
agonist treatments is to substitute a safer, longer-acting drug
for amore risky, short-acting one. Examples of agonist treatment
include methadone for opioid dependence and nicotine replace-
ment treatment for smoking cessation (Table 1). Agonist treat-
ment approaches have also been examined for cocaine depen-
dence (Herin et al., 2010). Most notably, dextroamphetamine
has reduced drug use in short-term clinical trials in cocaine
(Grabowski et al., 2004; Shearer et al., 2003) and methamphet-
amine users (Longo et al., 2010; Shearer et al., 2001). Amphet-
amines, similar to cocaine, increase synaptic dopamine levels
by inhibiting monoamine transporters and also by disrupting700 Neuron 69, February 24, 2011 ª2011 Elsevier Inc.the storage of dopamine in intracellular vesicles (Partilla et al.,
2006; Sulzer, 2011). The long-term safety and abuse liability of
amphetamines as a treatment for cocaine addiction remain to
be determined.
Another example of an agonist approach for cocaine depen-
dence is modafinil, which has stimulant-like effects. Modafinil
is a weak dopamine transporter inhibitor and increases synaptic
dopamine levels (Volkow et al., 2009). It also stimulates hypotha-
lamic orexin neurons, reduces GABA release, and increases
glutamate release (Martı´nez-Raga et al., 2008). While initial
randomized clinical trials with modafinil were promising for
cocaine addiction (Dackis et al., 2005), a multisite clinical trial
was negative (Anderson et al., 2009). However, modafinil may
act as a cognitive enhancing agent in stimulant-dependent indi-
viduals, improving learning through neural regions (insula and
ventromedial prefrontal and anterior cingulate cortices) impli-
cated in learning and cognitive control (Ghahremani et al., 2011).
2. Antagonist approaches. Antagonists block the effects of
drugs by either pharmacological or pharmacokinetic mecha-
nisms. Antagonist treatment approaches have been especially
useful for opioid drugs. An example of pharmacological antago-
nism is blockage of opioid effects by the m opioid antagonist
naltrexone or by buprenorphine, a partial m opioid agonist and
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rewarding effects of opioids and are effective for the treatment
for opioid addiction. Naltrexone also attenuates the rewarding
effects of alcohol by presumably blocking m opioid receptors
(Ray et al., 2008), and this mechanism probably contributes to
naltrexone’e efficacy for the treatment of alcohol addiction
(Sulzer, 2011). Similarly, varenicline, a partial agonist for the
alpha4beta2 nicotinic receptor, attenuates the rewarding effects
of nicotine (Patterson et al., 2009; Sofuoglu et al., 2009; West
et al., 2008) and is effective for the treatment of nicotine depen-
dence (Table 1).
More recently, immunotherapies have been developed for the
treatment of cocaine, methamphetamine, and nicotine addic-
tions (Orson et al., 2008). Immunotherapies antagonize drug
effects via pharmacokinetic mechanisms (LeSage et al., 2006).
The antibodies produced by immunotherapies sequester the
drug in the circulation and reduce the amount of drug and the
speed at which it reaches the brain. This results in attenuated
rewarding effects of the drug of abuse (Haney et al., 2010). While
initial clinical trials suggest some promise (Martell et al., 2005,
2009), to date the efficacy of vaccines has been undercut by
a substantial induction period required to achieve clinically
significant levels of circulating antibodies and only partial
blockade of drug effects even when antibody levels are maxi-
mized. An important limitation of vaccines is that the antibodies
produced are specific for a given drug of abuse, a characteristic
that will limit their clinical efficacy in polydrug abusers. The most
promising use of vaccine may be to prevent relapse in individual
whose drug use is limited to a single agent.
A potentially promising target for agonist and antagonist treat-
ment of cocaine addiction is the D3 dopamine receptor (Heid-
breder and Newman, 2010). Like the D2 dopamine receptor,
the D3 dopamine receptor is expressed at high levels in the stria-
tum, but compared to the D2 dopamine receptor, it is particularly
highly expressed in the ventral striatum. While D3 agonists
partially reproduce cocaine reinforcement, D3 antagonists or
partial agonists attenuate cocaine reinforcement (Achat-Mendes
et al., 2010). D3 partial agonists (CJB090, BP 897, and others)
can act like agonists and stimulate dopamine receptors when
endogenous levels of dopamine are low, as in cocaine with-
drawal. In contrast, when dopamine receptors are stimulated
after cocaine use, D3 partial agonists can act like antagonists
in blocking the effects of cocaine (Martelle et al., 2007). However,
drugs with D2 and D3 antagonistic properties have not demon-
strated clinical efficacy for drug or nonsubstance addictions
(Fong et al., 2008), D2/D3 antagonists have been associated
with promoting of gambling-related motivations in pathological
gambling (Zack and Poulos, 2007), and dopamine agonists
(including D3-preferring drugs) have been associated with
nonsubstance addictions like pathological gambling in the treat-
ment of Parkinson’s disease (Weintraub et al., 2010). As such,
the efficacies and tolerabilities of D3 partial agonists need careful
examination in people with addictions. Additionally, drugs that
target striatal dopamine function through indirect manners
(e.g., through serotonin 1B receptors) also warrant consideration
for treatment development (Hu et al., 2010).
3.Medications targeting negative reinforcement of drugs.Drug
addiction is associated with adaptive changes in multiple neuro-transmitter systems in the brain including dopamine, norepi-
nephrine, corticotrophin releasing hormone (CRH), GABA, and
glutamate (Chen et al., 2010; Koob and Le Moal, 2005). These
adaptive changes are thought to underlie the negative reinforc-
ing effects of abstinence from drug use that are clinically
observed as withdrawal symptoms, craving for drug use, and
negative mood states like anhedonia and anxiety. Increased
norepinephrine activity is associated especially with opioid and
alcohol withdrawal states. Development of sensitization to
drug-related cues, perceived as craving induced by drug cues,
probably involve adaptive changes in the dopamine, GABA,
and glutamate systems (Schmidt and Pierce, 2010). Reduction
in dopamine levels in the ‘‘reward’’ circuit is thought to mediate
anhedonia commonly observed following abstinence from drugs
(Treadway and Zald, 2011). Examples of medications targeting
negative reinforcement of drugs include methadone or bupre-
norphine, drugs that relieve opioid withdrawal symptoms.
Nicotine replacement products, bupropion, and the partial nico-
tinic agonist varenicline relieve nicotine withdrawal symptoms
and attenuate the negative mood states after smoking cessation
(Patterson et al., 2009; Sofuoglu et al., 2009). Acamprosate, an
approved medication for the treatment of alcohol dependence,
attenuates withdrawal symptoms and craving for alcohol (Gual
and Lehert, 2001).
Medications targeting the noradrenergic system have shown
promising results for treatments targeting withdrawal or relapse.
Preclinical and human laboratory studies suggest that lofexidine,
an alpha2-adrenergic agonist, may attenuate stress-induced
relapse in cocaine and opioid users (Highfield et al., 2001; Sinha
et al., 2007). Cocaine users with more severe withdrawal symp-
toms respond more favorably to propranolol, a beta-adrenergic
antagonist (Kampman et al., 2006). Clinical trials are underway to
test the efficacies of carvedilol, an alpha and beta-adrenergic
antagonist, and guanfacine, an alpha2-adrenergic agonist, in
treating cocaine or methamphetamine addiction.
Several agents targeting glutamate system are also under
investigation as potential treatment medications. Memantine,
a noncompetitive n-methyl-d-aspartate (NMDA) glutamate
receptor antagonist, has also shown efficacy in reducing cue-
induced craving for alcohol in alcohol dependent patients (Kru-
pitsky et al., 2007). In pathological gambling, memantine may
be efficacious and operate by reducing cognitive measures of
compulsivity (Grant et al., 2010). However, clinical trials with
memantine have demonstrated negative findings for alcohol
(Evans et al., 2007) and cocaine dependence (Bisaga et al.,
2010). A neutraceutical that targets the glutamate system is
N-acetyl cysteine, a natural compound used for the treatment
of acetaminophen overdose. N-acetyl cysteine’s proposed anti-
addictive effects include normalization of reduced extracellular
glutamate levels in the nucleus accumbens by stimulating the
cystine-glutamate antiporter (Baker et al., 2003). N-acetyl
cysteine has shown some positive results in small clinical trials
for cocaine and nicotine addiction and pathological gambling
(Grant et al., 2007; Knackstedt et al., 2009; Mardikian et al.,
2007). Larger studies are underway to test its efficacy in these
disorders. In addition, compounds targeting metabotropic gluta-
mate receptors have shown efficacy in blocking reinstatement of
drug use behavior in animal models for relapse. For example,Neuron 69, February 24, 2011 ª2011 Elsevier Inc. 701
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receptors, reduces self-administration and reinstatement of
drug-seeking behavior for nicotine (Liechti et al., 2007), alcohol
(Sidhpura et al., 2010; Zhao et al., 2006), and cocaine (Adewale
et al., 2006; Baptista et al., 2004). Several metabotropic gluta-
mate agonists are available for human use and should be evalu-
ated for the treatment of addictive disorders.
Medications Targeting Individual Vulnerability Factors
to Addiction
Individuals vary in their vulnerability to addiction. For example,
among those who had tried cocaine, only about 17% become
addicted (Wagner and Anthony, 2002). For alcohol, about 15%
of those who drink eventually become dependent, while 30%
of those who try smoking become addicted smokers. These
proportions are similar to those observed in preclinical models
of addiction (Belin et al., 2008). The individual factors contrib-
uting to vulnerability to addiction are complex and have not yet
been fully elucidated (George and Koob, 2010; Kreek et al.,
2005; Le Moal, 2009; Sinha, 2008; Uhl et al., 2009). Comorbid
psychiatric conditions and cognitive deficits are two examples
of individual vulnerability factors that could be targeted by phar-
macotherapies.
1. Treatments targeting comorbid psychiatric conditions.
Comorbidity exists between drug addiction and primary psychi-
atric disorders including schizophrenia, mood and anxiety disor-
ders, and attention-deficit hyperactivity disorder (Hasin et al.,
2007; Kessler et al., 2005). For example, among individuals
with schizophrenia, 40% to 60% abuse drugs or alcohol and
over 90% smoke cigarettes (George et al., 2002). Addicted indi-
viduals with comorbid psychiatric disorders tend to have poorer
outcomes than those without comorbidity (Brady and Sinha,
2005; Havassy et al., 2004; Potenza, 2007). One of the possible
mechanisms underlying this high comorbidity is self-medication,
which posits that individual with primary psychiatric disorders
use drugs or alcohol to relieve specific symptoms (e.g., negative
affect) or side effects of their treatment medications (e.g., seda-
tion). Alternatively, common genetic and other neurobiolgical
factors may lead to high comorbidity between addictions and
other psychiatric disorders (Chambers et al., 2001; Potenza
et al., 2005). Common vulnerability factors may include
increased impulsivity, reward sensitivity, and cognitive deficits.
One implication of comorbidity is that effective treatment of
psychiatric disorders may also reduce substance use, although
existing clinical trials indicate mixed results in this regard (Nunes
and Levin, 2004).
2. Medications targeting cognitive deficits. A large body of
evidence has documented cognitive deficits in chronic alcohol,
cocaine, methamphetamine, and cannabis users (Ersche et al.,
2006; Ersche and Sahakian, 2007; Goldstein and Volkow,
2002). Cognitive deficits may represent a particular challenge
for treatment-seeking users who require intact cognitive func-
tioning in order to engage in treatment and learn new behavioral
strategies in order to stop their drug use. As demonstrated
previously, cognitive deficits are associated with higher rates
of attrition and poor treatment outcome (Aharonovich et al.,
2006; Bates et al., 2006). Cognitive enhancement strategies
may be especially important early in the treatment by improving
their ability to learn, remember, and implement new skills and702 Neuron 69, February 24, 2011 ª2011 Elsevier Inc.coping strategies. The range of deficits that is found in addicted
individuals includes attention, working memory, and response
inhibition, functions that are attributed to the prefrontal cortex.
Cognitive functioning in the prefrontal cortex is modulated
by many neurotransmitters, including glutamate, GABA, acetyl-
choline, and monoamines: dopamine, serotonin, and norepi-
nephrine (Robbins and Arnsten, 2009). Many cognitive
enhancers targeting these neurotransmitters are in different
stages of development.
In a recent proof-of-concept study, we examined the efficacy
of galantamine, a cholinesterase inhibitor, as a cognitive
enhancer in abstinent cocaine users (M.S., J. Poling, and
K.M.C., unpublished data). Cholinesterase inhibitors, including
tacrine, rivastigmine, donepezil, and galantamine, have been
used for the treatment of dementia and other disorders charac-
terized by cognitive impairment, including Parkinson’s disease,
traumatic brain injury, and schizophrenia (Giacobini, 2004).
Cholinesterase inhibitors increase the synaptic concentrations
of acetylcholine (ACh), which lead to increased stimulation of
both nicotinic and muscarinic cholinergic receptors. Galant-
amine is also an allosteric modulator of the a7 and a4b2 nicotinic
ACh receptor (nAChR) subtypes (Schilstro¨m et al., 2007). In our
study, 10 day treatment with galantamine, compared to placebo,
improved the attention and working memory functions in absti-
nent cocaine users (M.S., J. Poling, and K.M.C., unpublished
data). These findings support the promise of galantamine as
a cognitive enhancer among cocaine users. This study did not
examine treatment effect on cocaine use because participants
had to be abstinent of drug use to allow accurate assessment
of galantamine on cognitive performance. Additional clinical
trials are underway to test the efficacy of galantamine in the
treatment of cocaine-addicted individuals.
Another promising medication for cognitive enhancement is
atomoxetine, a selective norepinephrine transporter (NET) inhib-
itor used for the treatment of attention deficit hyperactivity
disorder (ADHD). In prefrontal cortex, the NET is responsible
for the reuptake of norepinephrine as well as dopamine into
presynaptic nerve terminals (Kim et al., 2006). As a result, atom-
oxetine increases both NE and dopamine levels in the PFC, and
both actions may contribute to the cognitive-enhancing effects
of atomoxetine (Bymaster et al., 2002). Consistent with preclin-
ical studies (Jentsch et al., 2009; Seu et al., 2009), atomoxetine
improves attention and response inhibition functions in healthy
controls and patients with ADHD (Chamberlain et al., 2007,
2009; Faraone et al., 2005). Attention and response inhibition
functions are essential in optimum cognitive control needed to
prevent drug use, and atomoxetine in preclinical models dimin-
ished drug-seeking behaviors (Economidou et al., 2011). Both
attention and response inhibition are impaired in cocaine users
(Li et al., 2006; Monterosso et al., 2005). Whether these cognitive
functions can be improved and drug use curtailed with atomox-
etine remains to be determined in cocaine users.
In addition to cholinesterase inhibitors and atomoxetine, there
are many other potential cognitive enhancers include modafinil,
amphetamines, partial nAChR agonists, like varenicline, and
metabotropic glutamate agonists (Olive, 2010). The safety and
efficacy of these medications remain to be tested in clinical
studies with addicted individuals.
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While great progress has been made in identification of effective
pharmacotherapies and behavioral therapies for the addictions,
no existing treatment, delivered alone, is completely effective
(Carroll and Onken, 2005; Vocci et al., 2005). Thus, an important
strategy to enhance the efficacy of monotherapies is to combine
them with one or more alternative treatments (National Institute
on Drug Abuse, 2007). The results of combined treatments can
be additive, interactive, nonadditive (adding a second treatment
neither adds nor subtracts), or subtractive. Strategies for
choosing treatments to combine include (1) use of complemen-
tary efficacious treatments that address weakness in either
therapy alone, (2) use of efficacious treatments that target the
same processes in different ways, and (3) use of treatments
that are not efficacious alone but catalyze each other.
Frequently, these strategies involve combining a top-down
approach with a bottom-up intervention, such as combinations
of behavioral and pharmacotherapies (Figure 1).
There are multiple examples of behavioral and pharmacolog-
ical treatments having complementary effects. A classic
example is the combination of methadone maintenance with
behavioral therapies (McLellan et al., 1993; Peirce et al., 2006).
Without behavioral treatments, provision of methadone was
associated with early treatment failure and dropout (Ball and
Ross, 1991). Another example of this strategy involves antide-
pressant medications and cognitive behavioral therapy, each
of which has been demonstrated to reduce depression in
depressed smokers (Hall et al., 2002). Antidepressants are tar-
geted at neurotransmitter systems thought to underlie depres-
sion symptoms while CBT attempts to change behaviors and
cognitions associated with maintaining depression (DeRubeis
et al., 1999; DeRubeis et al., 2008). An example of catalytic, or
synergistic, treatment effects is provided by studies that
combine contingency management with tricyclic antidepres-
sants for cocaine abuse inmethadone-maintained patients (Kos-
ten et al., 2003; Poling et al., 2006). In both of these trials, neither
tricyclics nor contingency management was efficacious alone
but the combination yielded superior results compared to a stan-
dard treatment condition. Behavioral therapies may also work in
a complementary fashion, particularly in different stages of treat-
ment. For example, motivational interventions may help engage
individuals in treatment, contingency management may help
maintain individuals in treatment, and CBT may help with long-
term abstinence through relapse prevention and ‘‘sleeper
effects.’’ Although not linked to a specific therapy, there are
data to suggest that these different aspects of treatment
outcome are differentially associated with specific neural
circuits. For example, in cocaine-dependent individuals,
pretreatment fMRI measures of cognitive control were differen-
tially associated with outcome measures of retention and absti-
nence, with retention correlating with activation in the dorsolat-
eral prefrontal cortex (implicated in executive functioning) and
abstinence with activation in striatal and ventromedial prefrontal
cortical regions (implicated in reward processing and decision
making) (Brewer et al., 2008a). As this study involved a small
sample of subjects receiving combinations of behavioral and
pharmacological therapies, additional larger controlled studiesinvolving pre- and posttreatment imaging are needed to assess
more directly the relationships between specific treatments,
outcome measures, and neural functions.
Although it is tempting to speculate that specific combinations
of treatments (e.g., behavioral and pharmacological therapies
that theoretically engage top-down processes and bottom-up
processes, respectively; Figure 1) may have complementary
mechanisms of action, the precise mechanisms for synergism
between behavioral and pharmacotherapies are not well under-
stood and require direct investigation. Existing data offer some
insight. For example, consistent with the notion of pharmaco-
therapies working in a bottom-up fashion, bupropion treatment
of tobacco smokers was associated with less craving and dimin-
ished limbic activation to smoking cues when attempting to
resist craving, whereas placebo treatment did not demonstrate
changes in limbic activations (Culbertson et al., 2011). However,
in a study of tobacco smokers receiving treatment with bupro-
pion, practical group counseling, or pill placebo, individuals
receiving either active treatment differed from those receiving
placebo by showing greater reduction in glucose metabolism
posttreatment in the posterior cingulate cortex (Costello et al.,
2010). The decreased metabolism was not related to cigarette
usemeasures and appeared largely similar across the behavioral
and pharmacological therapies. As the posterior cingulate is an
integral component of the default mode network, the authors
speculated that effective treatments for nicotine dependence
may improve default mode network functioning, moving individ-
uals toward better goal-oriented states (Costello et al., 2010).
As children with ADHD show suppression of default mode pro-
cessing in response to stimulant treatment (Peterson et al.,
2009), the findings suggest that improved default mode process-
ing function may represent an important treatment target across
disorders characterized by impaired impulse control. Moreover,
as posterior cingulate activation during drug craving has been
associated with treatment outcome for cocaine dependence
(Kosten et al., 2006), the findings also suggest an important
role for posterior cingulate function for treatment outcome
across addictions and one that may also relate to the involve-
ment of the posterior cingulate in circuits related to emotional
and motivational processing (Sinha, 2008). Such possibilities
warrant direct examination.
Using Neuroscience to Investigate Treatment
Mechanisms
As reviewed above, traditional pharmacologic approaches to
addiction have focused on exploiting our understanding of the
specific actions of various neurotransmitters in the brain (e.g.,
dopamine for reward, opioids for pleasure, and adrenergic
neurochemicals for excitement) (Potenza, 2008). While
continuing to increase our understanding of the neurochemical
underpinnings of addictions remains important (particularly for
pharmacotherapy development), approaches to understanding
brain function related to addictions are increasingly focusing
on neural systems in the pathophysiologies of addictions.
Thus, incorporating pre- and posttreatment neuroimaging
measures into randomized clinical trials for addictions is partic-
ularly important if we are to identify neural predictors and
correlates of effective treatments for these disorders.Neuron 69, February 24, 2011 ª2011 Elsevier Inc. 703
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maging and clinical trials for addictions. While some are practical
(e.g., a relatively short time frame between evaluation/randomi-
zation and scanning requiring coordination between an interdis-
ciplinary research team, questions as to howbest tomanage and
consider recency of drug use—and potentially intoxication or
withdrawal—with respect to scanning), others are theoretical
(e.g., selecting measures that are theoretically related to the
therapies’ proposed mechanisms of action, a notion consistent
with selecting evaluative measures in clinical trials in general
[Walker et al., 2006]). An important advantage of fMRI in this
respect is the ability to monitor brain activity (via blood oxygen
level dependent [BOLD] signal) during task performance. As
such, specific fMRI paradigms may offer particular insights into
the mechanisms of action of particular therapies. For example,
effective contingency management, involving the delivery of
small immediate rewards based on positive short-term behav-
iors (e.g., drug abstinence) may be expected to involve changes
in reward processing that can be assessed through fMRI
paradigms like the monetary incentive delay task (Andrews
et al., 2010). Alternatively, specific aspects of CBT, such as
developing skills to cope with drug cues or triggers, might
involve changes in brain circuitry underlying regulation of craving
or cognitive control that may be assessed through different
fMRI paradigms (Brewer et al., 2008a; Janes et al., 2010;
Kober et al., 2010). Other fMRI paradigms (e.g., those probing
stress responsiveness) may be particularly well suited for
investigating mechanisms underlying mindfulness-based
therapies (Brewer et al., 2009; Sinha et al., 2005). Additionally,
advances in fMRI technology that facilitate real-time feedback
of regional brain activation may be used to investigate features
relevant to specific therapies (e.g., control of craving in
CBT and meditational states in mindfulness-based therapies)
(deCharms, 2008).
Conversely, novel methods of treatment delivery, such as
computer-assisted delivery of CBT (Carroll et al., 2008; Carroll
et al., 2009), may facilitate understanding of treatment mecha-
nisms through neuroimaging studies. Given the consistency
with which it is delivered, computerized treatment offers
a more robust and standardized form of treatment. The conse-
quent reduction in variance in the treatment variable may
increase the power of fMRI paradigms to detect processes
that are specific to this form of treatment, offering an advantage
in small-sample fMRI studies (Frewen et al., 2008). Also, compo-
nents of computer-delivered treatments could conceivably be
studied directly using fMRI.
Future Directions: Individual Differences,
Endophenotypes, and Treatment Matching
One current focus in optimizing treatment involves identifying
individual differences related to addiction treatment outcome
to guide the selection of therapies. While the consideration of
individual differences is not new (e.g., Project MATCH investi-
gated individual differences and treatment specificity with argu-
ably limited success [Cutler and Fishbein, 2005]), recent
approaches have considered individual differences from
a different perspective (e.g., as possible endophenotypes [Got-
tesman and Gould, 2003]). Some individual differences may704 Neuron 69, February 24, 2011 ª2011 Elsevier Inc.represent important targets for treatment development (e.g.,
potential endophenotypes like impulsivity or compulsivity [Dalley
et al., 2011]), whereas others (e.g., developmental stages, sex
differences, stage of the addiction process) may represent
important considerations when targeting or matching specific
treatments to specific individuals.
Endophenotypes represent particularly attractive therapeutic
targets as they may associate more closely to biological mecha-
nisms than do heterogeneous psychiatric disorders like addic-
tions (Fineberg et al., 2010; Gottesman and Gould, 2003). One
potential endophenotype relevant to addiction treatment is
impulsivity (Dalley et al., 2011). Preclinical data indicate that
impulsive tendencies prior to drug exposure both are linked to
ventral striatal dopamine function and predict the development
of addictive behaviors (Belin et al., 2008; Dalley et al., 2007).
Studies also link midbrain to ventral striatal dopamine pathways
to impulsivity in people (Buckholtz et al., 2010). Clinical data
suggest that impulsivity is associated with addiction severity
and that changes in addiction severity during treatment correlate
with changes in impulsivity (Blanco et al., 2009). Thus, targeting
impulsivity through behavioral or pharmacological mechanisms
that promote self-control warrants consideration. As elevated
impulsivity may predate addictive problems, such interventions
may be considered at early points in either the addictive process
or in development. This latter point seems particularly salient as
individual differences in self-control during childhood predict
important measures of functioning during adolescence and
into adulthood (Lehrer, 2009; Mischel et al., 1989). Furthermore,
as substance exposure during adolescence may lead to greater
impulsivity in adulthood (Nasrallah et al., 2009), early intervention
appears particularly important.
Targeting of specific factors may be complicated by the
complexities of the constructs. For example, impulsivity is
a multifaceted construct that factors into two or more domains
(Meda et al., 2009; Moeller et al., 2001). Two domains repeatedly
identified include those related to choice/decision making and
response disinhibition, and each appears relevant to addiction
(de Wit, 2009; Perry and Carroll, 2008; Potenza and de Wit,
2010; Reynolds et al., 2006; Verdejo-Garcı´a et al., 2008). The
specific domains of impulsivity may relate differentially to other
relevant psychobiological processes (e.g., reward processing
and cognitive control appear theoretically and biologically linked
to choice and response impulsivity, respectively) and thus
combinations of therapies that preferentially target each domain
may be needed to optimize treatments.
As self-report and behavioral measures of impulsivity have
been found to factor separately (Meda et al., 2009) and behav-
ioral and self-reported measures of the same constructs (e.g.,
temporal discounting) may not correlate with one another and
be differentially related to treatment outcome (Krishnan-Sarin
et al., 2007), a broad range of self-report, behavioral, and biolog-
ical assessments (including neurocognitive ones) may provide
the deep phenotyping that will be vital to treatment develop-
ments for addictions. Additionally, as brain circuits underlying
motivation, reward responsiveness, decision making, and
behavioral control are undergoing significant changes during
periods of increased addiction vulnerability such as adolescence
(Casey et al., 2010; Chambers et al., 2003; Rutherford et al.,
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important in this process.
Potential endophenotypes may underlie multiple kinds of
addictions (Frascella et al., 2010). However, specific drugs are
also associated with unique short- and long-term effects,
including potential neurotoxicities. Drug exposure may have
specific influences on brain structure and function, and such
changes warrant particular attention as they relate to treatment
development. For example, cocaine use has been associated
with metabolic impairments, with increasing chronicity of use
progressively influencing cortical regions from more ventral
and medial regions to more dorsal and lateral ones (Beveridge
et al., 2008). These findings are consistent with a broad range
of cognitive deficits observed in cocaine dependent individuals,
including on tasks associated with ventromedial prefrontal
cortical function (Bechara, 2003) as well as ones linked to dorso-
lateral prefrontal cortical function and associated with treatment
outcome measures of retention (Brewer et al., 2008a; Streeter
et al., 2008). Other brain differences, such as white matter integ-
rity (Lim et al., 2002, 2008; Moeller et al., 2005; Moeller et al.,
2007), have been observed in cocaine dependence and associ-
ated with disadvantageous decision making (Lane et al., 2010)
and treatment outcome (Xu et al., 2010). Both pharmacological
(Harsan et al., 2008; Schlaug et al., 2009) and behavioral (Tang
et al., 2010) approaches may alter white matter integrity. Thus,
white matter integrity may represent an underexamined thera-
peutic target in addictions. Additionally, investigating means
for altering synaptic connections, including rapid mechanisms
related to brief exposure to antiglutamatergic drugs (Li et al.,
2010), may aid addiction treatment development efforts, partic-
ularly as related to stress or other negative reinforcement
processes. These considerations underscore the promise of
developing and testing (both singly and in combination) pharma-
cological and behavioral treatments aimed at improving cogni-
tive functions such as attention, working memory, decision
making, and self-control. Relating the results of these treatments
to measures of impulsivity and brain function can provide
evidence for mechanisms of these treatments.
Endophenotypes may track closely with genetic factors, and
individual differences related to addictions and their treatments
may be influenced by genetic, environmental, or interactive influ-
ences (Goldman et al., 2005; Renthal and Nestler, 2008). As
commonly occurring allelic variants have been variably linked
to treatment outcomes for addictions (e.g., a functional variant
of the gene encoding the m opioid receptor has been associated
with opioid antagonist treatment outcome in some (Oslin et al.,
2003) but not other (Arias et al., 2008) studies of alcohol depen-
dence or heavy drinking) and specific environmental exposures
in conjunction with commonly occurring allelic variants may shift
the risk for developing and treating addictions (e.g., stress expo-
sure and serotonin-transporter-encoding genetic variants
interact to influence alcohol intake in young adults and may be
linked to ondansetron response in alcohol dependence [Johnson
et al., 2008; Laucht et al., 2009; Sinha, 2009]), it will be important
to carefully assessmultiple environmental and genetic measures
as related to treatment outcome. Furthermore, as timing of envi-
ronmental exposures may differentially impact individuals (e.g.,
influences of trauma early versus later in life) and do so ina sex- or culture-specific fashion, thorough assessments and
large samples involving targeted recruitment may be necessary
to optimize treatment strategies for individuals.
Drug-Related Brain Changes: Consideration
of Nonsubstance Addictions
Given the potential neurotoxic and neuroadaptation effects of
abused substances, understanding the neuroscience of addic-
tive processes may be enhanced by focusing on addictions
that do not necessarily involve use of psychoactive substances.
For example, obesity shares similarities with drug addictions
at neurobiological levels (e.g., with respect to striatal D2/D3
dopamine receptor function), and these similarities may inform
treatment and policy strategies (A.N. Gearhardt, C.M. Grilo,
R.J. DeLeone, K.D. Brownell, and M.N.P., unpublished data;
Vanbuskirk and Potenza, 2010). Pathological gambling also
demonstrates clinical and biological similarities with drug addic-
tions (Holden, 2010; Potenza, 2006, 2008). Consistently, treat-
ments, particularly those with proposed mechanisms of action
(e.g., modulation of neurotransmission in the mesolimbic dopa-
mine pathway by opioid receptor antagonists like naltrexone or
nalmefene or enhancing cognitive function via glutamatergic
agents like memantine) that target features observed across
addictions, appear efficacious for both substance and gambling
addictions (Brewer et al., 2008b; Cheon et al., 2008; Grant et al.,
2010; Potenza, 2008). Furthermore, among individuals with
pathological gambling, response to an opioid receptor antago-
nist appears strongly related to a family history of alcoholism
(Grant et al., 2008), suggesting a possible endophenotype
common to pathological gambling and alcoholism. However,
other features, such as executive processes involving dorsal
prefrontal cortical function, appear more impaired in individuals
with alcoholism than in those with gambling problems, consis-
tent with neurotoxic influences of alcohol (Lawrence et al.,
2009; Potenza, 2009b). As pathological gambling is unhindered
by drug-on-brain-substrate effects that may complicate the
treatment of substance addictions, it represents an important
disorder for better understanding substance addictions and their
treatments.
Conclusions
Although significant advances have been made over the past
several decades in the development of effective treatments for
addictions, they remain a substantial public health problem.
The development of neuroscience methodologies for assessing
brain structure and function provides an exciting opportunity for
applying these tools to understand and improve treatments.
Additional research efforts should define novel targets for treat-
ment (e.g., cognitive function, control of craving, impulsivity,
compulsivity, and/or self-control), implement tools for assessing
these targets over time (including self-report, behavioral, neuro-
cognitive/neural measures), and identify clinically relevant indi-
vidual differences that may be used to guide the selections of
therapies, including combinations of therapies that may operate
in complementary or synergistic fashions. As effects of drug use
on brain and brain function may be a major factor underlying
ability to benefit from treatment, direct investigation of drug-
related influences on brain structure and function are warranted
in translational and longitudinal studies. Concurrent investigationNeuron 69, February 24, 2011 ª2011 Elsevier Inc. 705
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